Reuters - Novartis AG's cancer drug Afinitor has been rejected for patients with kidney cancer by Britain's health costs watchdog, which says it is too pricey for the country's taxpayer-funded National Health Service (NHS).
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.